Lancora® (ivabradine) Tablets for Chronic Heart Failure Rate Control

What Lancora® Is and How It Works

Lancora® is the Canadian brand of ivabradine, a heart rate–lowering medicine used in chronic heart failure with reduced ejection fraction. It selectively inhibits the cardiac If current in the sinoatrial node. This slows resting heart rate without reducing cardiac contractility. The result is improved ventricular filling time and reduced hospitalization risk. If you plan to buy Lancora online, YouDrugstore offers licensed Canadian dispensing, including options for Lancora without insurance.

YouDrugstore is a licensed Canadian pharmacy headquartered in Manitoba, and our pharmacists review every prescription before dispensing. We work with licensed, vetted international partner pharmacies to provide authentic brand medicines, a broad selection, and affordable pricing.

Indication in Canada: Lancora is used for symptomatic chronic heart failure in adults with left ventricular ejection fraction at or below guideline thresholds who are in sinus rhythm and have an elevated resting heart rate despite guideline-directed therapy, or when beta‑blockers are not tolerated.

Form and route: film‑coated tablets taken by mouth, typically twice daily with food. Ivabradine does not treat arrhythmias and is not a beta‑blocker or calcium‑channel blocker.

Dosage and Usage

• Typical initiation: 5 mg twice daily with meals. Elderly or those prone to bradycardia may start at 2.5 mg twice daily.
• Titration: assess heart rate after 2 weeks; increase to 7.5 mg twice daily if resting heart rate remains above target and drug is well tolerated.
• Down‑titration: reduce by 2.5 mg twice daily if resting heart rate falls below 50 bpm or if bradycardia symptoms occur.
• Maximum dose: 7.5 mg twice daily.
• Administration: swallow tablets whole with food; avoid grapefruit and Seville oranges.
• Missed dose: take the next scheduled dose; do not double up.
• Do not use with strong CYP3A4 inhibitors (for example, ketoconazole, clarithromycin); avoid verapamil and diltiazem.
• Not for patients with acute decompensated heart failure, severe hepatic impairment, pacemaker dependence, or resting heart rate below prespecified thresholds before treatment.

• Storage: keep tablets at room temperature (15–30 °C), dry, and away from light.
• Home organization: store in the original bottle or blister to protect from moisture.
• Travel: carry in your hand luggage, in original labeled packaging for security checks.
• Heat and cold: do not leave in a hot car or freeze. Short exposures outside room temperature are usually acceptable if kept dry.
• Reminders: set phone alerts for twice‑daily dosing with meals.
• Refills: you can schedule reminders in your account so you reorder before running out.

Benefits and Savings

Ivabradine lowers heart rate without lowering blood pressure or contractility, which can help patients who cannot reach beta‑blocker targets. In chronic heart failure, it can reduce hospitalizations for worsening symptoms. Tablets are taken twice daily with meals, which fits most routines.

Ordering from a Canadian pharmacy can lower the Lancora price. Many customers see 60–80% savings versus typical US prices. If paying cash, Lancora without insurance may still be affordable, especially when choosing multi‑month supplies that can reduce the per‑month Lancora cost.

We also offer discreet packaging, prompt, express shipping, and easy reordering. Larger quantities and bulk promotions can improve your Lancora savings. See any current offers on our promotions page: Lancora coupon.

Side Effects and Safety

• Common: slow heart rate (bradycardia), dizziness, fatigue, headache.
• Vision: brief episodes of enhanced brightness or flickering lights (phosphenes), usually transient.
• Blood pressure changes, especially in those on multiple agents.
• Gastrointestinal discomfort or nausea.
• Leg cramps or musculoskeletal pain.

Serious but less common risks include symptomatic bradycardia, conduction disturbances, and atrial fibrillation. Stop and seek care for fainting, new or worsening irregular heartbeat, or severe dizziness. Do not use during pregnancy; use effective contraception. Avoid with strong CYP3A4 inhibitors and with verapamil or diltiazem. Limit grapefruit products. People with sick sinus syndrome, sinoatrial block, or third‑degree AV block without a functioning pacemaker should not use ivabradine.

Onset Time

Heart rate reduction begins within hours of the first dose, with near steady‑state effects in 3–4 days. Symptom improvements, such as less dyspnea or better exercise tolerance, may appear after 2–8 weeks as dosing stabilizes and background heart‑failure therapy remains optimized. Reductions in hospitalization risk emerge over months with consistent use.

Compare With Alternatives

Beta‑blockers remain foundational in heart failure, and many patients tolerate them at target doses. For those who cannot, ivabradine offers heart rate control without added negative inotropy. Nebivolol, branded as Bystolic®, lowers heart rate and blood pressure, and may improve symptoms, but can reduce contractility and cause fatigue or hypotension.

Renin‑angiotensin system blockers (ACE inhibitors or ARBs) address neurohormonal activation. Valsartan, available as Diovan®, helps reduce afterload and supports remodeling benefits. These agents are complementary to ivabradine when indicated. Some patients receive an angiotensin receptor–neprilysin inhibitor (sacubitril/valsartan) to further improve outcomes.

Unlike antianginal calcium‑channel blockers, ivabradine targets heart rate specifically and does not dilate coronary arteries or lower systemic blood pressure meaningfully at therapeutic doses.

Combination Therapy

• With beta‑blockers when tolerated; adjust doses to maintain safe resting heart rate and avoid symptomatic bradycardia.
• With ACE inhibitor, ARB, or ARNI as background guideline‑directed therapy.
• With mineralocorticoid receptor antagonists (e.g., spironolactone) for further morbidity reduction.
• With SGLT2 inhibitors in eligible patients as part of comprehensive heart‑failure care.
• Avoid combining with non‑dihydropyridine calcium‑channel blockers (verapamil, diltiazem) due to additive heart rate reduction and CYP3A4 interaction.

Patient Suitability and Cost-Saving Tips

Good candidates have symptomatic chronic heart failure with reduced ejection fraction, are in sinus rhythm, and have an elevated resting heart rate despite optimized background therapy. Patients who cannot reach beta‑blocker targets due to hypotension or fatigue may benefit from ivabradine’s selective heart rate control.

Not suitable: patients with severe hepatic impairment; resting heart rate below threshold prior to therapy; pacemaker dependence; acute decompensated heart failure; significant conduction disease without pacing; pregnancy and breastfeeding. Caution is needed in atrial fibrillation or with medications that slow heart rate or strongly inhibit CYP3A4. Review all medicines and supplements, including macrolides, azole antifungals, HIV protease inhibitors, and grapefruit products.

To manage the Lancora price, consider a 60‑, 90‑, or 180‑day supply to lower the monthly Lancora tablet cost. Turn on gentle reorder reminders in your account so you never run out. If paying cash, comparing Lancora price without insurance across strengths and pack sizes can help you find the best value through our Canadian pharmacy channel.

Authoritative Sources

Servier Canada Lancora product information

Health Canada Drug Product Database: Ivabradine (Lancora)

FDA Prescribing Information for ivabradine (US brand Corlanor)

Order Lancora® from YouDrugstore: add to cart, upload your prescription, and we ship with prompt, express shipping.

This page is educational and does not replace professional medical advice. Always speak with a qualified healthcare professional about diagnosis, treatment, and medication choices.